Clinical Trial Update: Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

View source ↗

Summary

A recruiting study evaluating whether multi-omics-based liquid biopsy can predict response to PD-L1 inhibitors after chemoradiotherapy in limited-stage small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer

Drugs mentioned

• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC) | Status: RECRUITING